Axon Enterprise
Valuation each multiple against its own 5-year range
Vs. peers Aerospace & Defense
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Axon Enterprise (AXON) | 23.71B | 93.61 | 6.30 | 0.00% |
| SpaceX (SPCX) | 1.74T | -505.10 | 9.82 | 0.00% |
| GE Aerospace (GE) | 319.95B | 36.13 | 18.26 | 0.57% |
| RTX Corp (RTX) | 256.62B | 30.92 | 3.71 | 1.48% |
| Lockheed Martin (LMT) | 130.63B | 20.08 | 12.98 | 2.44% |
| Boeing (BA) | 123.54B | 16.09 | 18.89 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 34.7% below Morningstar's fair value estimate.
Fair value
Though Axon Enterprise Inc appears cheap due to heavy downward pressure in the past year, we have capped its rating at 3 stars to factor in the possibility that it represents a value trap. The stock currently trades at a 22% discount to our quantitative fair value estimate of $392.09 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.
The company's solid growth bolsters our estimated fair value. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. Reflecting the firm's growth is its revenue 3-year growth of 32.3%, which ranks in the top 10% compared with global peers. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are undervalued.
On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 13.1%, a core component of profitability, falls in the bottom 20% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.
Economic moat
The company's excess returns on capital and superb profitability, which could persist for decades or more, warrant a wide economic moat rating. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.
Axon Enterprise discussion 0 comments